Pyxis Oncology Reports Q3 GAAP EPS of -$0.24, Exceeding Analyst Expectations
Pyxis Oncology (PYXS) reported third-quarter GAAP earnings per share of -$0.24, surpassing market estimates by $0.04. The results indicate a narrower-than-expected loss for the period. As of September 30, 2026, the company maintained a strong liquidity position with $57.0 million in cash, cash equivalents (including restricted cash), and short-term investments. This capital base includes proceeds from recent registered public offerings intended to support ongoing operations.
Tickers: $PYXS